Targets › FLG
1 program from 1 company in 5 trials: 3 Phase 3, 2 Phase 2; Immunology; next expected readout Dec 2026.
Aggregates keratin intermediate filaments and promotes disulfide-bond formation among the intermediate filaments during terminal differentiation of mammalian epidermis. (UniProt, P20930)
Open in Phaseline: the race on FLG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Celldex Therapeutics | Barzolvolimab Anti-filaggrin monoclonal antibody | FLG | Phase 3 | Chronic Spontaneous Urticaria; Chronic Inducible Urticaria; Atopic Dermatitis; Prurigo Nodularis | Dec 2026 |
Chronic Spontaneous Urticaria (2) Chronic Inducible Urticaria (1) Atopic Dermatitis (1) Prurigo Nodularis (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.